If ongoing randomized trials confirmed this paradigm, we may expect anti-HER2 ADCs to become useful treatment options for up to 70% of all mBC patients, with an important redefinition of current BC treatment algorithms [107]. This evidence concerns the gene ERBB2 and breast cancer.